{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:45:37Z","timestamp":1794336337263,"version":"4.9.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jacc.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:25:05Z","timestamp":1761924305000},"page":"549-565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance"],"prefix":"10.1016","volume":"87","author":[{"given":"Michelle M.","family":"Kittleson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrut V.","family":"Ambardekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew S.","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Nativi-Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Ruberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2025.09.004_bib1","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.004_bib2","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Castano","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.004_bib3","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci"},{"key":"10.1016\/j.jacc.2025.09.004_bib5","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.004_bib6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic hfpef phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib7","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.004_bib8","first-page":"3012","article-title":"Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fraction","volume":"12","author":"Inciardi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib9","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib10","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.004_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.004_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.004_bib13","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib14","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib15","first-page":"472","article-title":"A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing","volume":"94","author":"Muchtar","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.09.004_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib17","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.amjcard.2022.11.014","article-title":"Prevalence of orthopedic manifestations in patients with cardiac amyloidosis with a focus on shoulder pathologies","volume":"190","author":"Basdavanos","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/modpathol.2014.102","article-title":"Amyloid deposits derived from transthyretin in the ligamentum flavum as related to lumbar spinal canal stenosis","volume":"28","author":"Yanagisawa","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jacc.2025.09.004_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jor.2024.02.047","article-title":"Transthyretin amyloidosis in spinal canal stenosis: a systematic review","volume":"53","author":"Moore","year":"2024","journal-title":"J Orthop"},{"key":"10.1016\/j.jacc.2025.09.004_bib21","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.09.004_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2025.09.004_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.004_bib24","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/13506129.2021.2014448","article-title":"Same same, but different? The neurological presentation of wildtype transthyretin (ATTRwt) amyloidosis","volume":"29","author":"Kleefeld","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2025.09.004_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/jns.12403","article-title":"Peripheral neuropathy symptoms in wild type transthyretin amyloidosis","volume":"25","author":"Wajnsztajn Yungher","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jacc.2025.09.004_bib26","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1017\/cjn.2020.271","article-title":"Utility of neuropathy screening for wild-type transthyretin amyloidosis patients","volume":"48","author":"Russell","year":"2021","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jacc.2025.09.004_bib27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.004_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/anec.70026","article-title":"Diagnostic value of the voltage-to-mass ratio in biopsy-proven cardiac amyloidosis","volume":"29","author":"Jiang","year":"2024","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib29","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib30","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1016\/j.echo.2022.06.006","article-title":"Practical points for echocardiography in cardiac amyloidosis","volume":"35","author":"Cuddy","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.jacc.2025.09.004_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005588","article-title":"Echo parameters for differential diagnosis in cardiac amyloidosis: a head-to-head comparison of deformation and nondeformation parameters","volume":"10","author":"Pagourelias","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.09.004_bib32","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaccao.2024.10.013","article-title":"Biomarkers to predict abnormal technetium-99m pyrophosphate scans in patients with suspected transthyretin amyloidosis","volume":"7","author":"De Michieli","year":"2025","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacc.2025.09.004_bib35","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib36","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.mayocp.2021.04.023","article-title":"Artificial intelligence-enhanced electrocardiogram for the early detection of cardiac amyloidosis","volume":"96","author":"Grogan","year":"2021","journal-title":"Mayo Clin Proc"},{"issue":"40","key":"10.1016\/j.jacc.2025.09.004_bib37","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1093\/eurheartj\/ehaf387","article-title":"Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening tool","volume":"46","author":"Slivnick","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.004_bib38","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017761","article-title":"Machine learning to automatically differentiate hypertrophic cardiomyopathy, cardiac light chain, and cardiac transthyretin amyloidosis: a multicenter CMR Study","volume":"18","author":"Weberling","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.09.004_bib39","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1373\/clinchem.2004.046870","article-title":"Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice","volume":"51","author":"Katzmann","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2025.09.004_bib40","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41408-022-00732-3","article-title":"Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study","volume":"12","author":"Long","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jacc.2025.09.004_bib41","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/ejh.13458","article-title":"The value of screening biopsies in light-chain (AL) and transthyretin (ATTR) amyloidosis","volume":"105","author":"Cohen","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jacc.2025.09.004_bib43","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/eurheartj\/ehx047","article-title":"Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis","volume":"38","author":"Quarta","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.004_bib44","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.amjcard.2014.02.030","article-title":"Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis","volume":"113","author":"Fine","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib45","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: a systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.09.004_bib46","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"12","key":"10.1016\/j.jacc.2025.09.004_bib47","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.3390\/molecules26123649","article-title":"Combined subcutaneous fat aspirate and skin tru-cut biopsy for amyloid screening in patients with suspected systemic amyloidosis","volume":"26","author":"Hansen","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jacc.2025.09.004_bib48","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1002\/art.21902","article-title":"Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice","volume":"54","author":"van Gameren","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacc.2025.09.004_bib49","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2215\/CJN.02290508","article-title":"Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease","volume":"3","author":"Hutchison","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2025.09.004_bib50","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1007\/s12350-022-03059-5","article-title":"Radiopharmaceutical supply disruptions and the use of (99m)Tc-hydroxymethylene diphosphonate as an alternative to (99m)Tc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: an ASNC Information Statement","volume":"29","author":"Miller","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib51","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221082","article-title":"(99m)Tc bone-avid tracer cardiac scintigraphy: role in noninvasive diagnosis of transthyretin cardiac amyloidosis","volume":"306","author":"Khor","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.jacc.2025.09.004_bib52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib53","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/cpdd.789","article-title":"The bioequivalence of tafamidis 61-mg free acid capsules and tafamidis meglumine 4 x 20-mg capsules in healthy volunteers","volume":"9","author":"Lockwood","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jacc.2025.09.004_bib54","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-025-02159-z","article-title":"Acoramidis: first approval","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2025.09.004_bib55","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jacc.2024.11.042","article-title":"Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy","volume":"85","author":"Judge","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib56","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.124.072771","article-title":"Long-term efficacy and safety of acoramidis in ATTR-CM: initial report from the open-label extension of the ATTRibute-CM Trial","volume":"151","author":"Judge","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.004_bib57","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jns.12519","article-title":"Liver-directed drugs for transthyretin-mediated amyloidosis","volume":"27","author":"Brannagan","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jacc.2025.09.004_bib59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","article-title":"Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges","volume":"26","author":"Bruno","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2025.09.004_bib60","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","article-title":"Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis","volume":"56","author":"Tojo","year":"2006","journal-title":"Neurosci Res"},{"key":"10.1016\/j.jacc.2025.09.004_bib61","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2025.09.004_bib62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2022.10.012","article-title":"How to identify cardiac amyloidosis patients who might benefit from cardiac transplantation","volume":"11","author":"Ambardekar","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.004_bib64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.004_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2025.09.004_bib66","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B","volume":"85","author":"Witteles","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib67","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jacc.2024.11.015","article-title":"Outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial","volume":"85","author":"Fontana","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib68","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/j.jacc.2025.03.454","article-title":"Impact of vutrisiran on functional capacity and quality of life in transthyretin amyloidosis with cardiomyopathy","volume":"85","author":"Sheikh","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib69","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jchf.2025.03.017","article-title":"Current landscape of therapies for transthyretin amyloid cardiomyopathy","volume":"13","author":"Griffin","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib70","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.cardfail.2025.01.015","article-title":"A question in the era of multiple effective therapies for transthyretin amyloid cardiomyopathy (ATTR-CM): is transthyretin biology a driver of disease progression?","volume":"31","author":"Maurer","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib71","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib72","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jacc.2025.09.004_bib73","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib74","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2025.09.004_bib75","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.mayocp.2021.08.006","article-title":"Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy","volume":"97","author":"Barge-Caballero","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2025.09.004_bib76","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib77","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa2412309","article-title":"CRISPR-Cas9 gene editing with nexiguran ziclumeran for ATTR cardiomyopathy","volume":"391","author":"Fontana","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.004_bib79","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis-related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.004_bib80","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa2303765","article-title":"Antibody NI006 for cardiac transthyretin amyloid depletion. Reply","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2025.09.004_bib81","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2024.2420809","article-title":"PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study","volume":"32","author":"Suhr","year":"2025","journal-title":"Amyloid"},{"key":"10.1016\/j.jacc.2025.09.004_bib84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","volume":"30","author":"Girard","year":"2025","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2025.09.004_bib85","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.jacc.2025.03.542","article-title":"Early increase in serum transthyretin by acoramidis independently predicts improved survival in TTR amyloid cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib86","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib87","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2025.09.004_bib88","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1002\/ehf2.12989","article-title":"Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage","volume":"7","author":"Law","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2025.09.004_bib89","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.jcmg.2021.01.016","article-title":"Prognostic utility of echocardiographic atrial and ventricular strain imaging in patients with cardiac amyloidosis","volume":"14","author":"Huntjens","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.09.004_bib90","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.09.004_bib91","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","article-title":"Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy","volume":"149","author":"Porcari","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2025.09.004_bib92","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2025.09.004_bib93","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jacc.2024.04.011","article-title":"Prognostic value of a 6-minute walk test in patients with transthyretin cardiac amyloidosis","volume":"84","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib94","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamacardio.2024.0022","article-title":"Cardiopulmonary exercise testing in evaluating transthyretin amyloidosis","volume":"9","author":"Patel","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2025.09.004_bib95","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s11136-024-03723-y","article-title":"Health-related quality of life is an independent predictor of mortality and hospitalisations in transthyretin amyloid cardiomyopathy: a prospective cohort study","volume":"33","author":"Poledniczek","year":"2024","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jacc.2025.09.004_bib98","article-title":"Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy; final evidence report","author":"Wasfy","year":"2024","journal-title":"Institute for Clinical and Economic Review"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725077198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109725077198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:15:32Z","timestamp":1770844532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109725077198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0735109725077198"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2025.09.004","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transthyretin Cardiac Amyloidosis Evaluation and Management: 2025 ACC Concise Clinical Guidance","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}